Elekta (OTCMKTS:EKTAY) Shares Gap Down – Here’s Why

Elekta AB (OTCMKTS:EKTAYGet Free Report) gapped down before the market opened on Thursday . The stock had previously closed at $5.8650, but opened at $5.53. Elekta shares last traded at $5.53, with a volume of 108 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised Elekta from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Elekta currently has an average rating of “Reduce”.

Read Our Latest Analysis on Elekta

Elekta Trading Down 3.3%

The stock has a market cap of $2.03 billion, a price-to-earnings ratio of -34.38 and a beta of 1.01. The company has a quick ratio of 0.68, a current ratio of 0.87 and a debt-to-equity ratio of 0.47. The business’s 50 day simple moving average is $5.18 and its 200 day simple moving average is $5.71.

Elekta (OTCMKTS:EKTAYGet Free Report) last announced its quarterly earnings data on Thursday, August 27th. The company reported $0.07 EPS for the quarter. Elekta had a negative net margin of 3.32% and a positive return on equity of 11.11%. On average, research analysts expect that Elekta AB will post 0.43 EPS for the current fiscal year.

Elekta Company Profile

(Get Free Report)

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.

Read More

Receive News & Ratings for Elekta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elekta and related companies with MarketBeat.com's FREE daily email newsletter.